

La risposta di PwC

Dear Mr Ciccolella,

Due to contractual obligations of confidentiality, PwC cannot comment on specific projects.

In all of its work with the EU as a service provider, PwC strictly follows the relevant rules and obligations of the public procurement process and any work that we undertake for the EU is subject to an open bidding process and is a matter of public record.

Should you have any further questions as regards this contract we suggest you reach out to HADEA directly, the contracting authority.

Best regards,

Philippe Pierre, Partner

Industry & Public Sector Consulting Leader

Global lead Partner for the EU Institutions & EIB

PwC EU Services EEIG - General Manager

La risposta di HaDEA

Dear Mr Ciccolella,

Thank you again for your email and enquiry.

For your background, Antimicrobial resistance (AMR) has a direct impact on human and animal health and carries a heavy economic burden due to higher costs of treatments and reduced productivity caused by sickness. AMR is responsible for an estimated 33,000 deaths per year in the EU. It is also estimated that AMR costs the EU €1.5 billion per year in healthcare costs and productivity losses.

Often presented as the 'silent pandemic', we already know that antimicrobial resistance will continue to pose significant challenges in years, and even decades, to come. There is currently an issue with overprescribing antimicrobials.

AMR is a cross border issue. The One-Health dimension cannot be treated by a country or a Member State alone. The Commission aims to treat this at EU, but also at global level.

Concerning your questions:

1. How the tender process works and how PwC was assigned the contract.

The award of the contract for the Study on Bringing AMR Medical Countermeasures to the market followed the established procurement process for open procedures. The corresponding Call for Tenders was announced in advance and then published in eTendering - the EU Institutions' eProcurement Platform ([eTendering - Data \(europa.eu\)](https://eTendering-Data.europa.eu)). Once the period for submission of offers ended, the evaluation phase took place to award the contract to the most economically advantageous one.

1. How HaDEA evaluated – in the light of the tender specifications and criteria - that PwC might have a potential conflict of interest, as the results of the study will be highly sensitive to pharmaceutical companies that avail of services from other PwC entities.

The offer submitted by PwC was evaluated following the applicable methodology and on the basis of the award criteria as specified in the Tender Specifications. PwC declared not being in a conflict of interest that might negatively affect the performance of the contract.

2. When the study will be published and made available to the public.

Once the contract for the study finishes at the end of 2022, the results will be made available through their publication by the Publications Office of the European Union. This is expected to happen next year, most probably in February.

I hope you will find these replies helpful,

Many thanks again and have a nice day,

Hussein Sattaf

Hussein SATTAF

Head of Sector Communication



European Health and Digital Executive Agency (HaDEA)

Established by the European Commission

Boosting Europe by building, from earth to space, a healthy society, a digital economy and a competitive industry.

Unit HaDEA.C3 Staff, Communication and Support